Health economic models in hemophilia A and utility assumptions from a clinician's perspective

Michele Valente, Paolo A. Cortesi, Giuseppe Lassandro, Prasad Mathew, Jennifer Pocoski, Angelo C. Molinari, Lorenzo G. Mantovani, Paola Giordano

Research output: Contribution to journalArticle

Abstract

Background: The clinical benefits of prophylaxis in patients with hemophilia are well-established and include the following: reduced bleeding episodes, prevention of joint damage, decreased inhibitor development, and improved health-related quality of life. However, the cost-effectiveness of prophylaxis is still not clear. Procedures: We reviewed the published hemophilia prophylaxis economic models focusing on utility assumptions. Results: We found six cost-utility studies that compared prophylaxis and on-demand regimens. These studies reported remarkably different results, using utility values based on different assumptions and data sources. Conclusions: We suggest that cooperation among key stakeholders (clinicians, patient organizations and health-care decision makers) as a means of collecting evidence-based and experiential data to represent both the utility and the quality of life changes for patients with Hemophilia A who are treated with prophylaxis or receive on-demand treatments may represent a winning strategy with which to resolve the outstanding issues related to health technology assessments in the care of patients with hemophilia. Pediatr Blood Cancer 2015;62:1826-1831.

Original languageEnglish
Pages (from-to)1826-1831
Number of pages6
JournalPediatric Blood and Cancer
Volume62
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Economic Models
Hemophilia A
Health
Quality of Life
Biomedical Technology Assessment
Information Storage and Retrieval
Cost-Benefit Analysis
Patient Care
Joints
Organizations
Hemorrhage
Delivery of Health Care
Costs and Cost Analysis
Neoplasms

Keywords

  • Cost Utility Analysis (CUA)
  • Health Technology Assessment (HTA)
  • Health-related quality of life (HRQoL)
  • Hemophilia
  • Prophylaxis
  • Quality-adjusted life years (QALY)

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Valente, M., Cortesi, P. A., Lassandro, G., Mathew, P., Pocoski, J., Molinari, A. C., ... Giordano, P. (2015). Health economic models in hemophilia A and utility assumptions from a clinician's perspective. Pediatric Blood and Cancer, 62(10), 1826-1831. https://doi.org/10.1002/pbc.25543

Health economic models in hemophilia A and utility assumptions from a clinician's perspective. / Valente, Michele; Cortesi, Paolo A.; Lassandro, Giuseppe; Mathew, Prasad; Pocoski, Jennifer; Molinari, Angelo C.; Mantovani, Lorenzo G.; Giordano, Paola.

In: Pediatric Blood and Cancer, Vol. 62, No. 10, 01.10.2015, p. 1826-1831.

Research output: Contribution to journalArticle

Valente, M, Cortesi, PA, Lassandro, G, Mathew, P, Pocoski, J, Molinari, AC, Mantovani, LG & Giordano, P 2015, 'Health economic models in hemophilia A and utility assumptions from a clinician's perspective', Pediatric Blood and Cancer, vol. 62, no. 10, pp. 1826-1831. https://doi.org/10.1002/pbc.25543
Valente, Michele ; Cortesi, Paolo A. ; Lassandro, Giuseppe ; Mathew, Prasad ; Pocoski, Jennifer ; Molinari, Angelo C. ; Mantovani, Lorenzo G. ; Giordano, Paola. / Health economic models in hemophilia A and utility assumptions from a clinician's perspective. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 10. pp. 1826-1831.
@article{27a32f91d48f4fbcbc069130fdfc30b2,
title = "Health economic models in hemophilia A and utility assumptions from a clinician's perspective",
abstract = "Background: The clinical benefits of prophylaxis in patients with hemophilia are well-established and include the following: reduced bleeding episodes, prevention of joint damage, decreased inhibitor development, and improved health-related quality of life. However, the cost-effectiveness of prophylaxis is still not clear. Procedures: We reviewed the published hemophilia prophylaxis economic models focusing on utility assumptions. Results: We found six cost-utility studies that compared prophylaxis and on-demand regimens. These studies reported remarkably different results, using utility values based on different assumptions and data sources. Conclusions: We suggest that cooperation among key stakeholders (clinicians, patient organizations and health-care decision makers) as a means of collecting evidence-based and experiential data to represent both the utility and the quality of life changes for patients with Hemophilia A who are treated with prophylaxis or receive on-demand treatments may represent a winning strategy with which to resolve the outstanding issues related to health technology assessments in the care of patients with hemophilia. Pediatr Blood Cancer 2015;62:1826-1831.",
keywords = "Cost Utility Analysis (CUA), Health Technology Assessment (HTA), Health-related quality of life (HRQoL), Hemophilia, Prophylaxis, Quality-adjusted life years (QALY)",
author = "Michele Valente and Cortesi, {Paolo A.} and Giuseppe Lassandro and Prasad Mathew and Jennifer Pocoski and Molinari, {Angelo C.} and Mantovani, {Lorenzo G.} and Paola Giordano",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/pbc.25543",
language = "English",
volume = "62",
pages = "1826--1831",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Health economic models in hemophilia A and utility assumptions from a clinician's perspective

AU - Valente, Michele

AU - Cortesi, Paolo A.

AU - Lassandro, Giuseppe

AU - Mathew, Prasad

AU - Pocoski, Jennifer

AU - Molinari, Angelo C.

AU - Mantovani, Lorenzo G.

AU - Giordano, Paola

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: The clinical benefits of prophylaxis in patients with hemophilia are well-established and include the following: reduced bleeding episodes, prevention of joint damage, decreased inhibitor development, and improved health-related quality of life. However, the cost-effectiveness of prophylaxis is still not clear. Procedures: We reviewed the published hemophilia prophylaxis economic models focusing on utility assumptions. Results: We found six cost-utility studies that compared prophylaxis and on-demand regimens. These studies reported remarkably different results, using utility values based on different assumptions and data sources. Conclusions: We suggest that cooperation among key stakeholders (clinicians, patient organizations and health-care decision makers) as a means of collecting evidence-based and experiential data to represent both the utility and the quality of life changes for patients with Hemophilia A who are treated with prophylaxis or receive on-demand treatments may represent a winning strategy with which to resolve the outstanding issues related to health technology assessments in the care of patients with hemophilia. Pediatr Blood Cancer 2015;62:1826-1831.

AB - Background: The clinical benefits of prophylaxis in patients with hemophilia are well-established and include the following: reduced bleeding episodes, prevention of joint damage, decreased inhibitor development, and improved health-related quality of life. However, the cost-effectiveness of prophylaxis is still not clear. Procedures: We reviewed the published hemophilia prophylaxis economic models focusing on utility assumptions. Results: We found six cost-utility studies that compared prophylaxis and on-demand regimens. These studies reported remarkably different results, using utility values based on different assumptions and data sources. Conclusions: We suggest that cooperation among key stakeholders (clinicians, patient organizations and health-care decision makers) as a means of collecting evidence-based and experiential data to represent both the utility and the quality of life changes for patients with Hemophilia A who are treated with prophylaxis or receive on-demand treatments may represent a winning strategy with which to resolve the outstanding issues related to health technology assessments in the care of patients with hemophilia. Pediatr Blood Cancer 2015;62:1826-1831.

KW - Cost Utility Analysis (CUA)

KW - Health Technology Assessment (HTA)

KW - Health-related quality of life (HRQoL)

KW - Hemophilia

KW - Prophylaxis

KW - Quality-adjusted life years (QALY)

UR - http://www.scopus.com/inward/record.url?scp=84939564818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939564818&partnerID=8YFLogxK

U2 - 10.1002/pbc.25543

DO - 10.1002/pbc.25543

M3 - Article

C2 - 25976056

AN - SCOPUS:84939564818

VL - 62

SP - 1826

EP - 1831

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

ER -